Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 20/20 | 0.86 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.86 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.80 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1394760 | 0.95 | ALOX5AP (0.88) | ALOX5APPTGS1ALOX5LTC4SCYP3A4 | |
| SCHEMBL169599 | 0.93 | ALOX5AP (0.86) | ALOX5APPTGS1CYP3A4CYP2C9 | |
| SCHEMBL170252 | 0.92 | ALOX5AP (1.00) | ALOX5APPTGS1ALOX5LTC4SCYP3A4 | |
| SCHEMBL5529863 | 0.92 | ALOX5AP (0.74) | ALOX5APPTGS1ALOX5LTC4S | |
| SCHEMBL3469195 | 0.89 | ALOX5AP (0.86) | ALOX5APPTGS1ALOX5LTC4SCYP3A4 | |
| Fiboflapon SCHEMBL29379276 | 0.89 | ALOX5AP (1.00) | ALOX5APPTGS1ALOX5LTC4SCYP3A4 | |
| Fiboflapon SCHEMBL11820 | 0.89 | ALOX5AP (1.00) | ALOX5APPTGS1ALOX5LTC4SCYP3A4 | |
| SCHEMBL12526775 | 0.89 | ALOX5AP (0.90) | ALOX5APPTGS1ALOX5LTC4SCYP3A4 | |
| Fiboflapon SCHEMBL29723363 | 0.89 | ALOX5AP (1.00) | ALOX5APPTGS1ALOX5LTC4SCYP3A4 | |
| SCHEMBL1193698 | 0.89 | ALOX5AP (0.86) | ALOX5APPTGS1ALOX5LTC4S |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1943219-B1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS INC (US) | 2011-10-26 | — | — | EP | disclosed |